Skip navigation
Watchlist Sponsored By :


Current DateTime: 06:42:51 15 Nov 2009
LinksList Documentid: 24355697

FEATURED QUIZZES


Current DateTime: 06:42:51 15 Nov 2009
LinksList Documentid: 33793611
  • The Billionaire BFF's

      Philanthropists. Bridge partners. Hockey players. Which responses are based on facts from Buffett's and Gates' real lives?

  • The Many Myths of Coca-Cola

      Can you tell which statements are true, and which ones are just rumors?

  • Think You Understand Markets?

      We've selected some questions from the Financial Industry Regulatory Authority's test of investor knowledge. See how you do ...


Current DateTime: 06:42:51 15 Nov 2009
LinksList Documentid: 24890560
  • Winterizing Your Portfolio

      If 2009 was the winter of our discontent, will 2010 be a winter wonderland for investors? A lot depends on the recovery—or lack thereof.

  • Investor's Guide to Real Estate

      Some even say the long-awaited recovery is here. Regardless, buyers and sellers alike can profit from our guide.

  • Alternative Investing

      Stocks and bonds? Sure. But it's a big world out there for investors.

powered by digg
By: Peter Kang | 18 Jun 2007 | 04:46 PM ET
Text Size

Corporate actions and clinical trial data were some of the catalysts behind the most actively traded stocks on Monday.

Shares of Internet services firm Yahoo [YHOO  Loading...      ()   ] moved higher as investor speculated on potential corporate actions. Shares initially moved higher on unconfirmed reports published in an online media newsletter which said CEO Terry Semel could be close to resigning. Yahoo announced Semel's resignation after the close of trading.

CNBC's David Faber reported that Yahoo may be forced to explore strategic alternatives, with potential interested parties including News Corp., AT&T, Time Warner unit AOL, Microsoft and Comcast.

China Medical Technologies [CMED  Loading...      ()   ] reported solid fourth-quarter earnings on Monday, citing higher sales of diagnostic and tumor therapy systems. The tiny China-based medical device maker also said it expects a sharp rise in 2007 sales.

Graphics chipmaker Nvidia [NVDA  Loading...      ()   ] saw shares climb after the company said it bought back 3.3 million shares, according to documents filed with the Securities and Exchange Commission. Nvidia said the stock repurchase was part of its ongoing $1.7 billion buyback plan.

Citadel Broadcasting [CDL  Loading...      ()   ] shares rose after JP Morgan Securities said the radio broadcaster's recent acquisition of ABC Radio Holdings from Walt Disney [DIS  Loading...      ()   ] could boost the stock.

"From formerly being a small-market broadcaster with over 80% of its revenues generated in markets smaller than the top 50, the new Citadel will emerge with vastly greater exposure to the largest markets in the country," said analyst John Blackledge.

Genesco [GCO  Loading...      ()   ] shares gained after smaller rival Finish Line [FINL  Loading...      ()   ] said it would acquire the company for $1.5 billion, or $54.50 a share.

Genesco had recently rejected a sweetened takeover bid of $1.2 billion from Foot Locker.

Merger speculation for aluminum giant Alcoa [AA  Loading...      ()   ] continued on Monday after a London newspaper said metal mining titan BHP Billiton [BHP  Loading...      ()   ] was mulling a potential $40 million bid for Alcoa.

Among downside movers, Encysive Pharmaceuticals [ENCY  Loading...      ()   ] plunged after the U.S. Food and Drug Administration rejected the company's experimental treatment for high blood pressure in the lungs.

The FDA issued a third "approvable letter" for Thelin and said the drug did not demonstrate the effectiveness needed for approval as a treatment for pulmonary arterial hypertension (PAH) and advised the company to conduct additional clinical studies.

"We believe we adequately addressed the issue raised by the FDA in the second approvable letter and we are deeply disappointed in their decision," Encysive said in a prepared statement.

Encysive said the FDA decision may prompt it to make "significant reductions" in its infrastructure and workforce but will discuss plans at a later date.

The company's announcement comes on the heels of Gilead Sciences' [GILD  Loading...      ()   ] recent FDA approval of Thelin rival Letairis, which some analysts believe has the potential for blockbuster sales.

Peter Kang is a markets writer at CNBC.com and can be reached at .

© 2009 CNBC.com
Tools:
Print EmailAdd This share icon
  • digg share

CNBC HIGHLIGHTS

  • Warren Buffett and Bill Gates spoke to Columbia students, and Buffett made the students a startling offer.
  • Brian L. Roberts
  • For the chief of cable company Comcast, growth has been about making deals – generally very large deals.
  • Some companies may start using insurance to shift carbon risk from their balance sheets to maybe... yours?
  • The president and founder of Genesis Today wants to improve America’s health, and thinks Wal-Mart can help.
  • Switzerland's privacy watchdog is taking legal action to force Google to make changes to its Street View service.
  • A wealthy, distracted Texas driver crashed his million-dollar Bugatti Veyron sports car into a salt marsh, say police.
ADD COMMENTS
Remaining characters


Current DateTime: 01:03:48 15 Nov 2009
LinksList Documentid: 29778428

Current DateTime: 01:02:04 15 Nov 2009
LinksList Documentid: 29779196

Current DateTime: 01:02:04 15 Nov 2009
LinksList Documentid: 29779199

Current DateTime: 01:02:04 15 Nov 2009
LinksList Documentid: 29779198
  Data is a real-time snapshot  *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2009 CNBC, Inc.  All Rights Reserved.
A Division of NBC Universal
Thomson ReutersThomson Reuters